This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APOP Cellect Biotechnology (APOP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cellect Biotechnology Stock (NASDAQ:APOP) 30 days 90 days 365 days Advanced Chart Get Cellect Biotechnology alerts:Sign Up Key Stats Today's Range N/A50-Day Range$7.54▼$13.4052-Week Range N/AVolume17,400 shsAverage Volume479,845 shsMarket Capitalization$12.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.Read More… Receive APOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address APOP Stock News HeadlinesWaterloo startup secures funding for innovative women's health deviceMay 23, 2025 | msn.comSphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selectionMarch 31, 2025 | businesswire.comThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.June 15, 2025 | Weiss Ratings (Ad)Patent Term Adjustment and Double Patenting After In re CellectOctober 1, 2024 | reuters.comKrystal Biotech Inc.March 1, 2024 | wsj.comRaleigh/Durham Biotech NewsJune 23, 2023 | bizjournals.comSana Biotechnology Is Technically Overbought So Buy It LaterApril 19, 2023 | seekingalpha.comPiper Sandler says this biotech stock can outperform thanks to Alzheimer's treatmentApril 19, 2023 | cnbc.comSee More Headlines APOP Stock Analysis - Frequently Asked Questions How were Cellect Biotechnology's earnings last quarter? Cellect Biotechnology Ltd. (NASDAQ:APOP) issued its earnings results on Tuesday, November, 13th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.02. When did Cellect Biotechnology's stock split? Cellect Biotechnology shares split before market open on Tuesday, October 26th 2021. The 2-1 split was announced on Tuesday, October 26th 2021. The newly minted shares were issued to shareholders after the market closes on Tuesday, October 26th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Cellect Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Protalix BioTherapeutics (PLX), Advanced Micro Devices (AMD), NVIDIA (NVDA), Acasti Pharma (ACST) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings11/13/2018Today6/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:APOP CIK1671502 Webwww.cellect.co Phone(729) 974-1444Fax972-9767-8750Employees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / BookN/AMiscellaneous Outstanding Shares977,000Free FloatN/AMarket Cap$12.87 million OptionableNot Optionable Beta1.87 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:APOP) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellect Biotechnology Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellect Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.